Julien Rongere - AC Immune Senior Assurance
| ACIU Stock | USD 3.13 0.02 0.63% |
Executive
Julien Rongere is Senior Assurance of AC Immune
| Age | 46 |
| Phone | 41 21 345 91 21 |
| Web | https://www.acimmune.com |
AC Immune Management Efficiency
The company has return on total asset (ROA) of (0.2197) % which means that it has lost $0.2197 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7463) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Burke | Aldeyra | N/A | |
| Michael Mayberry | Contineum Therapeutics, Class | N/A | |
| Peter CPA | Contineum Therapeutics, Class | 50 | |
| Jamie MD | Annexon | 67 | |
| David Keenan | Amarin PLC | 58 | |
| Lynn MD | Lyell Immunopharma | 66 | |
| Marie Lindholm | Silence Therapeutics PLC | N/A | |
| Michael MBA | Annexon | 55 | |
| Adam MD | Alto Neuroscience, | 59 | |
| Francisco Esteva | Cellectis SA | 61 | |
| Michael MBA | Alto Neuroscience, | 52 | |
| Nabil Abadir | Amarin PLC | N/A | |
| Thomas Reilly | Amarin PLC | 52 | |
| Bryan Selby | Lyell Immunopharma | N/A | |
| Dr JD | Silence Therapeutics PLC | 65 | |
| Steven Doares | Cellectis SA | 65 | |
| Miriam Mason | Annexon | N/A | |
| Jason Hoffman | Alto Neuroscience, | N/A | |
| Kyung NamWortman | Cellectis SA | 55 | |
| Gianine Esposito | Silence Therapeutics PLC | N/A | |
| Sunil PharmD | Annexon | N/A | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.22 |
AC Immune Leadership Team
Elected by the shareholders, the AC Immune's board of directors comprises two types of representatives: AC Immune inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACIU. The board's role is to monitor AC Immune's management team and ensure that shareholders' interests are well served. AC Immune's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AC Immune's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nuno MD, Chief Officer | ||
| Christopher Roberts, Interim Fin | ||
| Gnther Staffler, Interim Development | ||
| Mark Danton, Executive Intelligence | ||
| Sonia Poli, Head Science | ||
| Oliver MD, VP Development | ||
| Matthias Maurer, Senior Counsel | ||
| Piergiorgio Donati, Chief Officer | ||
| Julian Snow, VP Development | ||
| Anke MD, Chief Officer | ||
| Pr MD, Chief Officer | ||
| Joshua Drumm, Head Relations | ||
| JeanFabien Monin, Chief Administrative Officer | ||
| Howard Donovan, Chief Officer | ||
| Alexandre Caratsch, General Counsel | ||
| Gary Waanders, Senior Communications | ||
| Andrea Pfeifer, CEO CoFounder | ||
| Marie KoscoVilbois, Chief Officer | ||
| Julien Rongere, Senior Assurance | ||
| Judith Moore, Global Communications | ||
| Madiha Derouazi, Chief Officer | ||
| Joseph Wettstein, Head Officer | ||
| David Hickman, Head SME |
ACIU Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AC Immune a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (16.72) % | ||||
| Current Valuation | 183.07 M | ||||
| Shares Outstanding | 100.6 M | ||||
| Shares Owned By Insiders | 38.00 % | ||||
| Shares Owned By Institutions | 24.80 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | (16.96) X | ||||
| Price To Book | 3.97 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.